Barclays’s Immunic IMUX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $37.4K | Buy |
4,025
+3,531
| +715% | +$48.6K | ﹤0.01% | 4637 |
|
|
2026
Q2 | $7.59K | Buy |
494
+251
| +103% | +$3.1K | ﹤0.01% | 4733 |
|
|
2026
Q1 | $2.7K | Buy |
243
+202
| +493% | +$1.81K | ﹤0.01% | 4825 |
|
|
2025
Q4 | $217 | Buy |
41
+3
| +8% | +$22 | ﹤0.01% | 5108 |
|
|
2025
Q3 | $335 | Buy |
38
+26
| +217% | +$229 | ﹤0.01% | 5220 |
|
|
2025
Q2 | $86 | Sell |
12
-5,617
| -100% | -$51.6K | ﹤0.01% | 5108 |
|
|
2025
Q1 | $61.4K | Sell |
5,629
-2,801
| -33% | -$30.2K | ﹤0.01% | 4568 |
|
|
2024
Q4 | $84.3K | Buy |
+8,430
| New | +$106K | ﹤0.01% | 4636 |
|
|
2023
Q2 | – | Sell |
-6,874
| Closed | -$102K | – | 4780 |
|
|
2023
Q1 | $102K | Sell |
6,874
-1,063
| -13% | -$19.7K | ﹤0.01% | 4163 |
|
|
2022
Q4 | $111K | Buy |
+7,937
| New | +$216K | ﹤0.01% | 4167 |
|
|
2022
Q3 | – | Sell |
-40
| Closed | -$1K | – | 4953 |
|
|
2022
Q2 | $1K | Sell |
40
-264
| -87% | -$16.9K | ﹤0.01% | 4939 |
|
|
2022
Q1 | $35K | Sell |
304
-1,968
| -87% | -$228K | ﹤0.01% | 4246 |
|
|
2021
Q4 | $217K | Buy |
2,272
+1,507
| +197% | +$136K | ﹤0.01% | 3538 |
|
|
2021
Q3 | $68K | Buy |
765
+567
| +286% | +$55.8K | ﹤0.01% | 4034 |
|
|
2021
Q2 | $24K | Sell |
198
-272
| -58% | -$37.6K | ﹤0.01% | 4438 |
|
|
2021
Q1 | $75K | Buy |
+470
| New | +$79.7K | ﹤0.01% | 4106 |
|
|
2020
Q4 | – | Sell |
-264
| Closed | -$47.4K | – | 5035 |
|
|
2020
Q3 | $50K | Buy |
264
+73
| +38% | +$12K | ﹤0.01% | 4598 |
|
|
2020
Q2 | $23K | Buy |
+191
| New | +$19.4K | ﹤0.01% | 5167 |
|
|
2020
Q1 | – | Hold |
0
| – | – | – | 6287 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6557 |
|
|
2019
Q3 | – | Sell |
-11
| Closed | -$1.47K | – | 6897 |
|
|
2019
Q2 | $1K | Sell |
11
-11
| -50% | -$1.44K | ﹤0.01% | 6843 |
|
|
2019
Q1 | $2K | Buy |
22
+18
| +450% | +$1.58K | ﹤0.01% | 6860 |
|
|
2018
Q4 | $0 | Sell |
4
-530
| -99% | -$62K | ﹤0.01% | 7112 |
|
|
2018
Q3 | $59K | Buy |
534
+528
| +8,800% | +$1.38M | ﹤0.01% | 5974 |
|
|
2018
Q2 | $15K | Sell |
6
-51
| -89% | -$118K | ﹤0.01% | 6335 |
|
|
2018
Q1 | $153K | Sell |
57
-22
| -28% | -$50.5K | ﹤0.01% | 5063 |
|
|
2017
Q4 | $189K | Buy |
+79
| New | +$175K | ﹤0.01% | 4737 |
|
|
2017
Q3 | – | Sell |
-142
| Closed | -$185K | – | 6929 |
|
|
2017
Q2 | $165K | Buy |
142
+141
| +14,100% | +$188K | ﹤0.01% | 4525 |
|
|
2017
Q1 | $1K | Sell |
1
-22
| -96% | -$40.3K | ﹤0.01% | 6588 |
|
|
2016
Q4 | $40K | Buy |
23
+20
| +667% | +$43.8K | ﹤0.01% | 5298 |
|
|
2016
Q3 | $8K | Buy |
3
+2
| +200% | +$4.94K | ﹤0.01% | 5865 |
|
|
2016
Q2 | $2K | Buy |
+1
| New | +$3.29K | ﹤0.01% | 5954 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 5968 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 5826 |
|
|
2015
Q3 | – | Sell |
-1
| Closed | -$5K | – | 6934 |
|
|
2015
Q2 | $7K | Buy |
+1
| New | +$9.5K | ﹤0.01% | 6273 |
|
|
2015
Q1 | – | Sell |
-1
| Closed | -$9.19K | – | 6685 |
|
|
2014
Q4 | $11K | Buy |
+1
| New | +$7.7K | ﹤0.01% | 6671 |
|
|
2014
Q3 | – | Sell |
-1
| Closed | -$9.44K | – | 7507 |
|
|
2014
Q2 | $6K | Buy |
+1
| New | +$7.02K | ﹤0.01% | 7062 |
|
Other funds holding IMUX
Barclays's IMUX Position: Q3 2026 in Review
Barclays increased its Immunic (IMUX) stake by 715% in Q3 2026, buying an estimated $48.6K and bringing the position to 4,025 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4637.
Barclays first reported a position in IMUX in Q2 2014 and has held it in 33 quarters since. The position peaked at $217K in Q4 2021. 15 funds tracked by Wall St. Rank hold IMUX as of Q3 2026.
- Barclays held 4,025 shares of Immunic worth $37.4K as of Q3 2026.
- Barclays bought 3,531 Immunic shares in Q3 2026, an estimated $48.6K.
- Immunic made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4637 holding.
- Barclays first reported a position in Immunic in Q2 2014 and has held it in 33 quarters since.
- Barclays's Immunic position peaked at $217K in Q4 2021.
- 15 funds tracked by Wall St. Rank held Immunic as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.